IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

View article:
IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Share

FDA accepts Allergan’s resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company’s resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults.

View article:
FDA accepts Allergan’s resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Share

Here Come the Robot Trail Runners…

Boston Scientific , a divison of Google ( Alphabet ?) that focuses on robotics, included a snippet of their humanoid robot trail running in a recent presentation. It actually does a nice little Gordy shuffle, the energy-minimized forward motion many of us resort to in the final miles of a hundo.

Taken from:
Here Come the Robot Trail Runners…

Share

Isagenix International concludes annual event, raises funds for children’s charity organization

Isagenix International, a global health and wellness company, ended its annual Celebration 2015 Breakthrough event in San Diego today by raising more than $565,000 for Make-A-Wish® through fundraising and generous Associate and corporate pledges.

Originally posted here:
Isagenix International concludes annual event, raises funds for children’s charity organization

Share